Insider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells 18,416 Shares of Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 18,416 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the sale, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. This represents a 0.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Organogenesis Stock Performance

NASDAQ ORGO opened at $3.68 on Wednesday. The firm has a 50-day moving average of $3.39 and a 200-day moving average of $2.98. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The stock has a market cap of $487.89 million, a PE ratio of -61.33 and a beta of 1.73. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The company had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same quarter last year, the company posted $0.02 EPS. On average, sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Institutional Trading of Organogenesis

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC raised its stake in Organogenesis by 251.7% in the 3rd quarter. Barclays PLC now owns 94,809 shares of the company’s stock worth $271,000 after purchasing an additional 67,855 shares in the last quarter. Wellington Management Group LLP raised its stake in Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after purchasing an additional 17,842 shares in the last quarter. State Street Corp raised its stake in Organogenesis by 0.6% in the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares in the last quarter. Verition Fund Management LLC raised its stake in Organogenesis by 542.8% in the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after purchasing an additional 66,448 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Organogenesis in the 3rd quarter worth about $36,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.